Companies To Watch
-
Companies To Watch: Endevica Bio
3/1/2022
Endevica Bio is developing a new treatment for cachexia, a severe wasting disease critical to patients’ survival in cancer and other conditions.
-
Companies To Watch: MiroBio
2/1/2022
MiroBio is precisely targeting checkpoint receptors with agonist antibodies for better treatments in autoimmunity.
-
Companies To Watch: Qlaris Bio
1/4/2022
Qlaris Bio is striking at an unaddressed target in the intraocular pressure of glaucoma.
-
Companies To Watch: Graphite Bio
11/1/2021
Graphite Bio focuses on precise repair of genes that cause sickness, starting with Sickle Cell Disease.
-
Companies To Watch: Atea Pharmaceuticals
10/1/2021
Atea Pharmaceuticals is creating new nucleotide antivirals, including one the company is jointly developing with Roche to fight COVID-19.
-
Companies To Watch: AltruBio
9/1/2021
AltruBio’s new approach — regulating a checkpoint to mediate T cells in immune diseases — can surprise people more familiar with checkpoint-blocking cancer treatments now on the market.
-
Companies To Watch: AMO Pharma
8/2/2021
AMO Pharma is applying “de-risked” compounds as potential medicines for rare diseases in brain development.
-
Companies To Watch: NervGen Pharma
7/1/2021
NervGen Pharma is going beyond preclinicals to human trials for a drug that could repair and regrow neurons.
-
Companies To Watch: IM Therapeutics
6/1/2021
Our company to watch this month is IM Therapeutics, which focuses on developing small molecule therapies for Type 1 diabetes, celiac disease, and other autoimmune conditions.
-
Companies To Watch: Lyra Therapeutics
5/3/2021
Our company to watch this month, Lyra Therapeutics, is focused on controlling chronic ENT conditions with precise drug elution and long action.